During the recent decades, the CVD therapeutics market has experienced remarkable progress and witnessed vast scientific innovation. First, this was seen with the launch of statins like Lipitor (atorvastatin), and more recently with the introduction of protein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. Meantime, other areas, for instance, the heart failure remain poorly treated.

Hypertension and dyslipidemia sectors continue to exhibit robust development within the overall current pipeline and, despite rapidly evolving generic drugs sector, there is also a high degree of innovation.

Presently, the CVD drugs pipeline is extensive with more than 1,400 products in active development.

In the coming years, the world’s CVD market landscape is projected to pass through a period of substantial changes following key anticipated approvals, acquisitions and patent expiries.